• Cybin held its annual and special shareholder meeting on Sept. 22, 2026.
• Shareholders backed a plan to set the board size at eight directors.
• Investors also endorsed changing the legal name to Helus Pharma, with the change set to take effect Oct. 1, 2026.
• Zeifmans was appointed as auditor until the next annual shareholder meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001833141-26-000081), on September 23, 2026, and is solely responsible for the information contained therein.